Shilpa Patil’s Post

Precision treatment has revolutionized cancer therapy in recent years. By utilizing the unique molecular profile of each patient, treatment strategies can be personalized to maximize therapeutic efficacy while minimizing side effects. A recent review provides valuable insights into the critical aspects of precision treatment in HCC, including therapeutic #biomarkers, molecular classifications, and the complexities of the tumor microenvironment. Check out the review here: https://lnkd.in/eDcC2vew #precisiononcology #oncology #biomarkers #cancerresearch

The OS improvement with the nivolumab-based regimen reached the trial’s primary end point. Additionally, the safety profile of nivolumab plus ipilimumab was comparable with prior reports of each agent. https://lnkd.in/eR4e9cY5 #gicsm #cancer #oncology

Overall Survival and Exploratory Biomarker Analyses in Patients With HR+/HER2+ Metastatic Breast Cancer Receiving Abemaciclib Plus Trastuzumab ± Fulvestrant vs Trastuzumab Plus Chemotherapy Clinical Cancer Research TAKE-HOME MESSAGE This study reported an update of the phase II monarcHER study, which revealed that fulvestrant, trastuzumab, and abemaciclib improved progression-free survival compared with chemotherapy plus trastuzumab in patients with advanced or metastatic HR+/HER2+ breast cancer. The three treatment groups included arm A (abemaciclib, trastuzumab, and fulvestrant), arm B (abemaciclib and trastuzumab), and arm C (chemotherapy and trastuzumab). In this update, the overall survival (OS) outcomes were reported. The median OS was 31.1, 29.2, and 20.7 months in arms A, B, and C, respectively. No new safety signals were identified. In these updated results from the monarcHER study, treatment with abemaciclib plus trastuzumab with or without fulvestrant improved OS compared with chemotherapy plus trastuzumab.

Last weekend, our Breast Cancer Index team presented data at #ASCO24 that suggests a significant group of #BreastCancer patients and their providers may make inappropriate extended endocrine therapy (EET) treatment decisions if they only base the decision on test results that are intended to inform chemotherapy benefit. One size doesn't fit all when developing treatment plans, as deciding whether to extend endocrine therapy – and balancing potential EET side effects with risk of recurrence – is an incredibly personal decision. And as the only genomic test recognized by major guidelines to predict which patients are likely to benefit from EET, we’re proud that the Breast Cancer Index test is trusted to help make that choice. Read more on the data here: https://lnkd.in/gzEeDWbR [meetings.asco.org]

📖 Thrilled to share our first publication in 2024 in “Breast Cancer Research and Treatment” entitled „Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?“ The prognostic power, calibration, and predictive value of the CTS5 was tested in patients of the prospective ABCSG-06 and -06a  trials. The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of endocrine therapy (ET). Apart from evaluating the prognostic value and calibration accuracy of CTS5, the aim of this study was to clarify if this score is able to identify patients at higher risk for LDR who will benefit from extended ET.   👉 Access the publication here: https://lnkd.in/dakSQ-jA 👉 Or take a look at all ABCSG-publications on our website via https://lnkd.in/dfVb8Rcs Michael Gnant #ABCSGbefirst #Breastcancer #CancerResearch #ClinicalTrials #ClinicalResearch

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study Our last paper 🎉 -563 patients were included in the analysis: 213 received cisplatin/gemcitabine alone, 350 received cisplatin/gemcitabine plus durvalumab. -Cis Gem Durva OS 14.8 months versus Cis Gem 11.2 months [HR 0.63 p = 0.0002] -In line with the results of the TOPAZ-1 trial, adding durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of OS and PFS in a real-world setting of patients with advanced BTC. Lorenza Rimassa @fornarolorenzo @lonardisara @nigermonica Antonuzzo Lorenzo @riminimargherita

In abstracts presented at ASCO 2024, the annual meeting for the American Society of Clinical Oncology (ASCO), researchers discovered that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were significantly beneficial in treating #obesity among women with breast #cancer. They also explored GLP-1RA use for anthracycline or HER-2 inhibitor-treated #patients with breast cancer and #diabetes, finding a reduction in major adverse #cardiovascular events. https://lnkd.in/ec6NHfGy

FDA recently approved nogapendekin alfa inbakicept-pmln (Anktiva), used in conjunction with bacillus Calmette-Guérin (BCG), marking a significant advancement in the treatment of non–muscle-invasive bladder cancer (NMIBC) unresponsive to BCG alone. #Anktiva #BCGUnresponsiveDisease #FDAApproval #NMIBC #NogapendekinAlfaInkakiceptpmln

Compared with the pembrolizumab combination, tiragolumab-based treatment did not show improvements in PFS (HR, 1.27; 95% CI, 1.02-1.57) or OS (HR, 1.33; 95% CI, 1.02-1.73) across the intent-to-treat population. https://lnkd.in/eEFCycyj #NSCLC #cancer #oncology

Groundbreaking #Oncology Trial Results Published on January 23rd, 2024 🎉 We are thrilled to share the publication of three Phase 2 clinical trial results in the fight against cancer, covering advanced breast cancer, metastatic urothelial cancer, and advanced soft tissue sarcoma. These studies highlight innovative treatments and promising outcomes for patients facing these challenging conditions. 1. 🎗️ Breast Cancer Breakthroughs: In a Phase 2 study of poziotinib for HER2-positive advanced breast cancer, patients who had previously undergone anti-HER2 regimens showed an objective response rate (ORR) of 30%. Despite facing adverse events like diarrhea and rash, a median progression-free survival (PFS) of up to 4.9 months was reported. #BreastCancerAwareness #HER2Positive 2. 💪 Fighting Metastatic Urothelial Cancer: The combination of sacituzumab govitecan and pembrolizumab has shown an impressive objective response rate of 41% in a Phase 2 trial for metastatic urothelial cancer, with a clinical benefit rate of 46% and a median duration of response of 11.1 months. This beacon of hope for patients signifies a remarkable advancement in treatment. #UrothelialCancerFight #CancerResearch 3. 🏋️♂️ Progress in Soft Tissue Sarcoma: A single-arm Phase 2 trial investigating pazopanib combined with durvalumab in metastatic or recurrent soft tissue sarcoma reported an overall response rate of 30.4% and a median progression-free survival of 7.7 months. This study marks a significant step forward in treating this challenging condition. #SarcomaResearch #InnovativeTreatments For more detailed information on these groundbreaking studies, follow this link https://lnkd.in/dsZBeCP3. Let's keep the conversation going! Like, share, and follow for more updates on how we're making strides in cancer treatment together. Your support can help spread hope and awareness to those in need. #CancerCare #ClinicalTrials #MedicalInnovation